nafamostat   Click here for help

GtoPdb Ligand ID: 4262

Synonyms: CKD-314 | CKD314 | FUT-175 | Nafabelltan®
Approved drug PDB Ligand
nafamostat is an approved drug (Japan only)
Compound class: Synthetic organic
Comment: Nafamostat is a guanidinobenzoate-containing inhibitor, with activity against a range of serine proteases. Some data is attached to nafamostat mesylate (PubChem CID 5311180).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 4
Rotatable bonds 5
Topological polar surface area 140.57
Molecular weight 347.14
XLogP 2.98
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES NC(=Nc1ccc(cc1)C(=O)Oc1ccc2c(c1)ccc(c2)C(=N)N)N
Isomeric SMILES NC(=Nc1ccc(cc1)C(=O)Oc1ccc2c(c1)ccc(c2)C(=N)N)N
InChI InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)
No information available.
Summary of Clinical Use Click here for help
Used in Japan as an anticoagulant and to treat pancreatic cancer.
SARS-CoV-2 and COVID-19: In Japan, a combination therapy of nafamostat plus favipiravir is being evaluated in patients with COVID-19 pneumonia (clinical trial jRCTs031200026) [5]. Favipiravir is being included for its antiviral action, and nafamostat is being proposed to reduce SARS-CoV-2 entry by inhiiting the host protease TMPRSS2 [3,7], and to additionally counteract COVID-19-associated thrombosis via its anticoagulant activity.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Serine protease inhibitor.